Trial Profile
A randomized, multicentre, open-label, 6-month study to explore the efficacy and safety of enteric coated mycophenolate sodium (Myfortic) in combination with two corticosteroid regimens for the treatment of lupus nephritis
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 20 Jan 2022
Price :
$35
*
At a glance
- Drugs Mycophenolate sodium (Primary) ; Methylprednisolone
- Indications Lupus nephritis
- Focus Therapeutic Use
- Acronyms MyLupus
- Sponsors Novartis Pharma A.G.
- 14 Feb 2015 Status changed from recruiting to completed, according to European Clinical Trials Database record
- 30 Jun 2012 Planned number of patients changed from 96 to 98 as reported by European Clinical Trials Database.
- 01 Dec 2011 Results published in Lupus.